Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Depreciation & Amortization (IS) (2021 - 2025)

Historic Depreciation & Amortization (IS) for Xeris Biopharma Holdings (XERS) over the last 5 years, with Q3 2025 value amounting to $338000.0.

  • Xeris Biopharma Holdings' Depreciation & Amortization (IS) rose 1009.77% to $338000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 141.4%. This contributed to the annual value of $1.2 million for FY2024, which is 1820.0% down from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Depreciation & Amortization (IS) stood at $338000.0, which was up 1009.77% from $325000.0 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Depreciation & Amortization (IS) ranged from a high of $391000.0 in Q3 2023 and a low of $281000.0 during Q2 2024
  • In the last 5 years, Xeris Biopharma Holdings' Depreciation & Amortization (IS) had a median value of $337000.0 in 2021 and averaged $338631.6.
  • Its Depreciation & Amortization (IS) has fluctuated over the past 5 years, first tumbled by 2720.21% in 2024, then soared by 1565.84% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Depreciation & Amortization (IS) (Quarter) stood at $349000.0 in 2021, then increased by 5.16% to $367000.0 in 2022, then dropped by 2.18% to $359000.0 in 2023, then decreased by 12.81% to $313000.0 in 2024, then rose by 7.99% to $338000.0 in 2025.
  • Its Depreciation & Amortization (IS) was $338000.0 in Q3 2025, compared to $325000.0 in Q2 2025 and $315000.0 in Q1 2025.